MedTrace Logo

IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors

NCT03665129 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2022-01-27

No results posted yet for this study

Summary

This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

IPH5401 and Durvalumab

IPH5401 and durvalumab

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Innate Pharma

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-07
Primary Completion
2021-02-24
Completion
2021-02-24
FDA Drug
Yes

Countries

  • United States
  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03665129 on ClinicalTrials.gov